CMA - AstraZeneca doesn't expect Alexion deal to see antitrust concerns in remaining reviews

AstraZeneca (AZN) is said not to expect to see antitrust issues for its planned purchase of Alexion (ALXN) in the geographies where the deal is still being approved.Filings with the European Commission and the UK Competition and Markets Authority (CMA) aren't expected to raise competition concerns, according to Dealreporter, citing sources familiar. The deal still needs approvals in UK, EU and Japan.The companies haven't formally filed with regulators in Brussels or London yet.Last month, the U.S. FTC cleared AstraZeneca's acquisition of Alexion.

For further details see:

AstraZeneca doesn't expect Alexion deal to see antitrust concerns in remaining reviews